OncoCyte Statistics

Total Valuation

OncoCyte has a market cap or net worth of $48.82 million. The enterprise value is $44.92 million.

Market Cap	48.82M
Enterprise Value	44.92M

Important Dates

The next estimated earnings date is Monday, November 11, 2024, before market open.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

OncoCyte has 16.84 million shares outstanding. The number of shares has increased by 45.19% in one year.

Shares Outstanding	16.84M
Shares Change (YoY)	+45.19%
Shares Change (QoQ)	+55.74%
Owned by Insiders (%)	6.81%
Owned by Institutions (%)	7.79%
Float	6.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	27.62
Forward PS	29.22
PB Ratio	1.77
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	43.91
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.16.

Current Ratio	1.38
Quick Ratio	1.30
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-432.68

Financial Efficiency

Return on equity (ROE) is -101.76% and return on invested capital (ROIC) is -34.75%.

Return on Equity (ROE)	-101.76%
Return on Assets (ROA)	-16.67%
Return on Capital (ROIC)	-34.75%
Revenue Per Employee	$22,239
Profits Per Employee	-$800,087
Employee Count	46
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.17% in the last 52 weeks. The beta is 1.00, so OncoCyte's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	+14.17%
50-Day Moving Average	3.07
200-Day Moving Average	2.96
Relative Strength Index (RSI)	38.91
Average Volume (20 Days)	26,373

Short Selling Information

The latest short interest is 189,327, so 1.12% of the outstanding shares have been sold short.

Short Interest	189,327
Short Previous Month	179,641
Short % of Shares Out	1.12%
Short % of Float	2.77%
Short Ratio (days to cover)	7.46

Income Statement

In the last 12 months, OncoCyte had revenue of $1.02 million and -$36.80 million in losses. Loss per share was -$3.91.

Revenue	1.02M
Gross Profit	314,000
Operating Income	-21.63M
Pretax Income	-36.35M
Net Income	-36.80M
EBITDA	-20.22M
EBIT	-21.63M
Loss Per Share	-$3.91

Full Income Statement

Balance Sheet

The company has $9.26 million in cash and $3.67 million in debt, giving a net cash position of $5.59 million or $0.33 per share.

Cash & Cash Equivalents	9.26M
Total Debt	3.67M
Net Cash	5.59M
Net Cash Per Share	$0.33
Equity (Book Value)	22.70M
Book Value Per Share	1.70
Working Capital	2.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$18.00 million and capital expenditures -$496,000, giving a free cash flow of -$18.50 million.

Operating Cash Flow	-18.00M
Capital Expenditures	-496,000
Free Cash Flow	-18.50M
FCF Per Share	-$1.10

Full Cash Flow Statement

Margins

Gross Margin	30.69%
Operating Margin	-2,114.76%
Pretax Margin	-3,532.75%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-1,651.42%

Dividends & Yields

OncoCyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-45.19%
Shareholder Yield	-45.19%
Earnings Yield	-72.87%
FCF Yield	-36.62%

Analyst Forecast

The average price target for OncoCyte is $4.06, which is 40.00% higher than the current price. The consensus rating is "Buy".

Price Target	$4.06
Price Target Difference	40.00%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Jul 25, 2023
Split Type	Reverse
Split Ratio	0.05:1

Scores

OncoCyte has an Altman Z-Score of -6.25 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.25
Piotroski F-Score	3